GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) Stock Price & News

Q2 2027 earnings • in 5 days

See details

GLAXO:NSE

GlaxoSmithKline Pharmaceuticals Ltd

2 508,70 ₹

-0,25%

(-6,40) 1D

30 հոկ, 15:30:02 GMT+5:30 · INR

All symbols

	Symbol	Price	Change	% Change

Generating top insights for GLAXO...

Open

2 527,60 ₹

High

2 528,90 ₹

Low

2 479,30 ₹

Mkt. cap

424,99 մլրդ

Avg. vol.

64,38 հզր

Volume

56,35 հզր

Dividend

2,27%

Quarterly dividend

14,25 ₹

Ex-dividend date

29 մյս, 2026 թ.

P/E ratio

39,79

52-wk high

3 120,70 ₹

52-wk low

2 088,10 ₹

EPS

63,05 ₹

Shares outstanding

169,41 մլն

No. of employees

3 հզր

Open

2 527,60 ₹

High

2 528,90 ₹

Low

2 479,30 ₹

Mkt. cap

424,99 մլրդ

Avg. vol.

64,38 հզր

Volume

56,35 հզր

Dividend

2,27%

Quarterly dividend

14,25 ₹

Ex-dividend date

29 մյս, 2026 թ.

P/E ratio

39,79

52-wk high

3 120,70 ₹

52-wk low

2 088,10 ₹

EPS

63,05 ₹

Shares outstanding

169,41 մլն

No. of employees

3 հզր

Related stocks

IPCALAB

IPCA Laboratories Ltd

Glenmark Pharmaceuticals Ltd

2 298,70 ₹

-1,72%

News stories

From web sources and news partners

Seeking Alpha

44 րոպե առաջ

Nasdaq suffers a 3% loss as investors rotate out of technology (COMP:IND:)

Eagle-Tribune

28 րոպե առաջ

The sell-off for tech stocks deepens and drags Wall Street toward its worst day since June

Yahoo Finance

1 ժամ առաջ

Micron Became One of the 10 Biggest Holdings in S&P 500 Index Funds. What Does That Mean for the Stock?

Reuters

1 ժամ առաջ

Nasdaq faces $2 trillion wipeout in October as AI spending fears deepen

Profile

GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia

About GlaxoSmithKline Pharmaceuticals Ltd

CEO-

Employees3,1 հզր

Founded13 նոյ, 1924 թ.

Headquarters-

Sector-

Websiteindia-pharma.gsk.com

All values in INR	2025 թ. սեպ	2025 թ. դեկ	2026 թ. մրտ	2026 թ. հնս
Revenue	9,80 մլրդ	10,41 մլրդ	9,95 մլրդ	9,38 մլրդ
Cost of goods sold	3,56 մլրդ	3,64 մլրդ	3,69 մլրդ	3,28 մլրդ
Cost of revenue	3,56 մլրդ	3,64 մլրդ	3,69 մլրդ	3,28 մլրդ
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,38 մլրդ	1,52 մլրդ	2,95 մլրդ	1,59 մլրդ
Operating expense	3,06 մլրդ	3,26 մլրդ	2,84 մլրդ	3,31 մլրդ
Total operating expenses	6,62 մլրդ	6,90 մլրդ	6,53 մլրդ	6,59 մլրդ
Operating income	3,18 մլրդ	3,51 մլրդ	3,43 մլրդ	2,80 մլրդ
Other non operating income	335,70 մլն	321,20 մլն	-1,09 մլրդ	437,60 մլն
EBT including unusual items	3,54 մլրդ	4,00 մլրդ	3,73 մլրդ	3,22 մլրդ
EBT excluding unusual items	3,51 մլրդ	3,82 մլրդ	2,94 մլրդ	3,22 մլրդ
Income tax expense	965,10 մլն	1,04 մլրդ	952,41 մլն	852,70 մլն
Effective tax rate	27,26%	26,08%	25,53%	26,44%
Other operating expenses	1,51 մլրդ	1,54 մլրդ	-236,82 մլն	1,56 մլրդ
Net income	2,57 մլրդ	2,96 մլրդ	2,78 մլրդ	2,37 մլրդ
Net profit margin	26,28%	28,39%	27,92%	25,27%
Earnings per share	-	-	-	14,00
Interest and investment income	-	-	657,30 մլն	-
Interest expense	-5,10 մլն	-11,90 մլն	-6,12 մլն	-9,70 մլն
Net interest expenses	-5,10 մլն	-11,90 մլն	651,18 մլն	-9,70 մլն
Depreciation and amortization charges	174,30 մլն	203,20 մլն	131,74 մլն	158,40 մլն
EBITDA	3,35 մլրդ	3,61 մլրդ	3,52 մլրդ	2,89 մլրդ
Gain or loss from assets sale	-	-	-	-

Ask anything